Indications |
Oral Allergic conditions Adult: 2 mg every 4-6 hr. Child: 2-5 yr: 0.5 mg; 6-12 yr: 1 mg, dose to be taken every 4-6 hr. Max Dosage: Adult: 12 mg daily. Child 6-12 yrs: 6 mg daily; 2-5 yrs: 3 mg daily. |
Contraindications |
Premature infants or full-term neonates. |
Warnings / Precautions |
Pregnancy; lactation; severe CV disorders; asthma. May impair ability to drive or operate machinery. Angle-closure glaucoma, urinary retention, prostatic hypertrophy, pyloroduodenal obstruction; renal and hepatic impairment; elderly; epilepsy. |
Adverse Reactions |
Exfoliative dermatitis. Sedation; antimuscarinic effects, CNS depression and disturbances; occasionally, paradoxical CNS stimulation; psychomotor impairment; headache; palpitations and arrhythmias; convulsions, sweating, myalgia, paraesthesias, extrapyramidal symptoms, tremor; sleep and GI disturbances. Rarely, hypersensitivity reactions and blood disorders; tinnitus, hypotension; hair loss. Injections may cause transient hypotension or CNS stimulation and irritation. |
Drug Interactions |
CNS depressants eg, alcohol, barbiturates, hypnotics, opioid analgesics; anxiolytic sedatives and neuroleptics; other antimuscarinics; MAOIs; betahistine; ototoxic drugs. See Below for More dexchlorpheniramine Drug Interactions |
Lab Interactions |
May interfere with skin testing. |
Mechanism of Actions |
Dexchlorpheniramine is the dextrorotatory isomer of chlorpheniramine and has approximately twice its activity by wt. |
Administration |
May be taken with or without food. |
ATC Classification |
R06AB02 - dexchlorpheniramine ; Belongs to the class of substituted alkylamines used as systemic antihistamines. |
Available As |
|
Dexchlorpheniramine
Post Review about Dexchlorpheniramine Click here to cancel reply.
Dexchlorpheniramine Containing Brands
Dexchlorpheniramine is used in following diseases
Drug - Drug Interactions of Dexchlorpheniramine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.